ReviewThe Lancet. Infectious diseases2005
Treatment and vaccines for severe acute respiratory syndrome.
Review in The Lancet. Infectious diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 76 citations in OpenAlex.
- Integrated health surveillance and early warning systems in China under the One Health perspective: progress and challenges.Science in One Health · 2025Review
- Practices, Knowledge, and Attitudes of Chinese University Students Toward Traditional Chinese Herbal Medicine for the Control of COVID-19.Infection and drug resistance · 2022Article
- Covid 19-the 21st Century Pandemic: The Novel Coronavirus Outbreak and the Treatment Strategies.Advanced pharmaceutical bulletin · 2022Review
- Article
- COVID-19 challenges and its therapeutics.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates.Molecules (Basel, Switzerland) · 2021Review
- The Role of Immunogenetics in COVID-19.International journal of molecular sciences · 2021Review
- An integrative look at SARS‑CoV‑2 (Review).International journal of molecular medicine · 2021Review
- The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).BioMed research international · 2021Review
- Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.PloS one · 2021Article
- Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.Clinical & translational immunology · 2021Review
- Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.Scientific reports · 2020Article
- Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study.Transboundary and emerging diseases · 2020Article
- Access to intensive care in 14 European countries: a spatial analysis of intensive care need and capacity in the light of COVID-19.Intensive care medicine · 2020Article
- Article
- Overview of coronavirus disease 2019: Treatment updates and advances.Journal of the Chinese Medical Association : JCMA · 2020Review
- A comprehensive review about SARS-CoV-2.Future virology · 2020Review
- A Narrative Review of COVID-19: The New Pandemic Disease.Iranian journal of medical sciences · 2020Review
- COVID-19 in otolaryngologist practice: a review of current knowledge.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2020Review
- Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The causative agent of severe acute respiratory syndrome (SARS), which affected over 8000 individuals worldwide and was responsible for over 700 deaths in the 2002-2003 outbreak, is a coronavirus that was unknown before the outbreak. Although many different treatments were used during the outbreak, none were implemented in a controlled fashion. Thus, the optimal treatment for SARS is unknown. Since the outbreak, much work has been done testing new agents against SARS using in-vitro methods and animal models. In addition, global research efforts have focused on the development of vaccines against SARS. Efforts should be made to evaluate the most promising treatments and vaccines in controlled clinical trials, should another SARS outbreak occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.